Canadian drugmaker Valeant announced Monday the departure of chief executive Michael Pearson after the firm came under fire for its pricing and accounting practices.

Activist investor Bill Ackman will also join the board, the company said in a statement, days after warning it was also at risk of a debt default and slashed its earnings forecast.